Abstract
Inference of clinical phenotypes is a fundamental task in precision medicine, and has therefore been heavily investigated in recent years in the context of electronic health records (EHR) using a large arsenal of machine learning techniques, as well as in the context of genetics using polygenic risk scores (PRS). In this work, we considered the epigenetic analog of PRS, methylation risk scores (MRS), a linear combination of methylation states. Since methylation states are influenced by both environmental and genetic factors, we hypothesized that MRS would complement PRS and EHR-based machine-learning methods, improving overall prediction accuracy. To evaluate this hypothesis, we performed the largest assessment of methylation risk scores in clinical datasets to be conducted to date. We measured methylation across a large cohort (n=831) of diverse samples in the UCLA Health biobank, for which both genetic and complete EHR data are available. We constructed MRS for 607 phenotypes spanning diagnoses, clinical lab tests, and medication prescriptions. When added to a baseline set of predictive features, MRS significantly improved the imputation of 139 outcomes, whereas the PRS improved only 22 (median improvement for methylation 10.74%, 141.52%, and 15.46% in medications, labs and diagnosis codes, respectively, whereas genotypes only improved the labs at a median increase of 18.42%). We added significant MRS to state-of-the-art EHR imputation methods that leverage the entire set of medical records, and found that including MRS as a medical feature in the algorithm significantly improves EHR imputation in 37% of lab tests examined (median R2 increase 47.6%). Finally, we replicated several MRS in multiple external studies of methylation (minimum p-value of 2.72 × 10−7) and replicated 22 of 30 tested MRS internally in two separate cohorts of different ethnicity. In summary, our work provides a comprehensive evaluation of MRS in comparison to PRS and EHR imputation on the largest dataset consisting of methylation, genotype, and EHR data. Our publicly available results and weights show promise for methylation risk scores as clinical and scientific tools.
Competing Interest Statement
There is a conflict of interest I.H. is the president of Clarity Healthcare Analytics Inc, a company that assists hospitals with extracting and using data from their electronic medical records. The company currently owns the rights to the PDW software that was used to extract data from the electronic health record. I.H. receives research funding from Merck Pharmaceuticals. M.C. is a consultant for Edwards Lifesciences (Irvine, CA) and Masimo Corp (Irvine, CA), and has funded research from Edwards Lifesciences and Masimo Corp. He is also the founder of Sironis and he owns patents and receives royalties for closed loop hemodynamic management technologies that have been licensed to Edwards Lifesciences. E.H. is senior vice president of AI/ML at OptumLabs (Minnetonka, MN). The other authors declare no competing interests concerning this article.
Funding Statement
See manuscript for funding statements
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Retrospective data collection and analysis was approved by the UCLA IRB. We include a reference to [67] which includes the following: Patient Recruitment and Sample Collection for Precision Health Activities at UCLA is an approved study by the UCLA Institutional Review Board (UCLA IRB). IRB#17-001013. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Methylation risk scores are available at https://github.com/cozygene/EHR_MRS_UCLA
